Search results
FDA Approves First Two Interchangeable EYLEA® Biosimilars – Biocon’s Yesafili™ (aflibercept-jbvf)...
JD Supra· 4 days agoOn May 20, 2024, the FDA approved the first two interchangeable biosimilars of Regeneron’s EYLEA® (aflibercept) – Biocon Biologics and Mylan’s...
FDA panel backs Guardant’s blood test for colon cancer
MedTech Dive via Yahoo Finance· 2 days agoGuardant expects the FDA to decide whether to approve Shield later this year. This story was...
Could drugs like Ozempic and Wegovy help people live longer? Some experts see them as potential...
Fortune via AOL· 5 hours agoMost experts agree that these drugs would need to be studied more extensively for each potential...
FDA considers 2nd blood test for colon cancer — but advisers note concerns
Becker’s Hospital Review· 2 days agoFDA advisers have recommended the approval of Guardant Health's blood test to detect colon or rectal cancers — but it also raised some concerns, NBC News reported May 23.
The Biggest Publicly Traded Biotech Company
Insider Monkey via Yahoo Finance· 2 hours agoIn this article, we will be discussing the biggest publicly traded biotech company that ranks at the top of our free list of the 20 Biggest Publicly...
FDA gives Neuralink another shot at brain chip – report
The Register· 5 days agoAmerica's Food and Drug Administration (FDA) has reportedly approved Neuralink to implant an updated...
Mirat Shah, MD, on Elacestrant's FDA Approval for Breast Cancer With ESR1 Mutations
MedPage Today· 5 days agoFDA scientists published a detailed rationale for the approval of elacestrant (Orserdu), the first...
Altria's NJOY Submits Application to FDA for Vaping Device With Access-Restriction Tech
Market Watch· 5 days agoThe NJOY ACE 2.0 device incorporates access-restriction technology via Bluetooth connectivity to authenticate the user before unlocking the device, the company said Monday. NJOY has filed a ...
Ovarian cancer drug developer's stock cut in half after it files for FDA approval - Boston Business...
The Business Journals· 2 days agoNeedham cancer drug developer Verastem Oncology saw its stock plunge over 60% Friday morning as of...
FDA approves 2 Eylea biosimilars
Becker’s Hospital Review· 6 days agoThe FDA granted approval to Biocon Biologics' drug Yesafili and Samsung Bioepis and Biogen's drug Opuviz, the agency announced May 20. The two drugs are biosimilars for Eylea ...
